Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

Season 5 Episode 44  ·  Sep 23, 2021, 07:59 PM

Headliner
Share
Subscribe

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Share
Subscribe
Next
Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air